By integrating G9a inhibition with cannabinoid receptor activation, this work aims to elucidate the interplay between epigenetic regulation and endocannabinoid signaling, providing insights into novel therapeutic strategies for AD. This evidence concerns the gene EHMT2 and Alzheimer disease.